News|Articles|October 5, 2026

New Research on Black Seed Oil Examines the Link Between Gut Bacteria and the Stress Response

Listen
0:00 / 0:00

Key Takeaways

  • TriNutra’s multi-study package associates ThymoQuin 500 mg daily with cortisol lowering, improved DHEA:cortisol balance, sleep-quality gains, and signals across immune, metabolic, and cardiovascular measures.
  • An in vitro gut microbiota model showed selective, concentration-dependent shifts: marked Streptococcus thermophilus expansion, preservation of Lactiplantibacillus plantarum and Akkermansia muciniphila, and >94% inhibition of Klebsiella pneumoniae.
SHOW MORE

TriNutra is presenting new data on its standardized black seed oil ingredient at SupplySide Global, adding to a growing body of research on how gut bacteria and the body's stress response may influence each other.

Editor’s Note: This article has been updated on October 13, 2026 to include additional studies and context.

TriNutra, a supplier of standardized black seed oil ingredients, is using SupplySide Global 2026 to present what it describes as a more complete picture of the relationship between gut bacteria and the body's stress response, built around its ingredient ThymoQuin.

The company has been studying the ingredient, standardized to at least 3% thymoquinone, across several small clinical and laboratory investigations examining stress, sleep, mood, and microbiome markers.¹

"What is exciting about this research is that we are beginning to see a more complete picture of how the gut and the body's response to stress may be connected," said Morris Zelkha, CEO of TriNutra. "Each study adds another piece to that picture and gives us new areas to investigate. We plan to continue investing and expanding the science behind ThymoQuin and its adaptogenic resilience, microbiome recalibration, and its proven long-term safety, which we are referring to as the Gut-Stress-Axis."

What New Research Is TriNutra Presenting on the Gut-Stress Axis?

The company points to 4 clinical and laboratory investigations examining ThymoQuin's effects across stress, cortisol, sleep, mood, immune, metabolic, cardiovascular, and microbiome outcomes.¹

Newly reported figures include cortisol reductions ranging from 23% to 44%, a 29% improvement in the ratio of dehydroepiandrosterone to cortisol, a 31% improvement in sleep quality, and a 66% increase in Streptococcus thermophilus, alongside earlier findings on blood pressure, gut microbiome composition, cortisol, and mood.¹

TriNutra attributes these effects to a single 500 mg daily dose and describes the ingredient as formulated to meet United States Pharmacopeia monograph standards for identity and purity.

How Does the Ingredient Appear to Affect Gut Bacteria?

The most detailed new data comes from an in vitro laboratory study, now posted as a bioRxiv preprint, examining ThymoQuin’s effect on gut bacteria across 3 independent batches.2

Within an intermediate concentration range of 0.25% to 0.5%, the ingredient increased growth of Streptococcus thermophilus by as much as 53-fold, preserved Lactiplantibacillus plantarum and Akkermansia muciniphila, and inhibited Klebsiella pneumoniae by more than 94%.1,2 The preprint notes that this selectivity was concentration-dependent: at the lowest concentrations tested, effects on some organisms were minimal, and at the highest concentration, the ingredient’s antimicrobial activity became broader and less selective, affecting beneficial and non-beneficial bacteria alike.2

The preprint’s authors identify 0.125% to 0.5% ThymoQuin as the most promising window and describe the overall response as hormetic.2 TriNutra says these concentrations correspond to those expected in the gut after its recommended 500 mg daily dose, pointing instead to human data as supportive: in a published randomized, placebo-controlled study of 37 endurance runners, 500 mg daily for four weeks was associated with a 66% higher relative abundance of S. thermophilus and an 8-point higher microbiome composite score compared with placebo.3

What Should Manufacturers Weigh Before Relying on This Data?

The in vitro design cannot speak to clinical outcomes on its own, and the company’s own data show that the favorable microbial selectivity it highlights was dose- and concentration-dependent rather than uniform.2 Manufacturers evaluating the ingredient for stress- or gut-related product claims will want to see the completed peer-reviewed publication and independent replication before treating the current figures as settled.

The laboratory work does not stand alone, however. ThymoQuin has two published human studies: the randomized, placebo-controlled trial in 37 experienced marathon runners that associated 500 mg daily with fewer upper respiratory tract complaints, better mood, and lower cortisol after endurance training and competition, and an 8-week randomized, placebo-controlled trial in moderately stressed adults that reported improvements in cortisol, DHEA, and sleep quality.3,4 Because both studies came from the same research team, further backing on stress physiology, ideally from independent investigators and larger populations, would still strengthen the case.

References

  1. TriNutra. TriNutra to showcase new research examining the gut-stress axis and ThymoQuin at SupplySide Global. October 5, 2026. Accessed October 5, 2026. Press release provided via email.
  2. Papini FS, Zettner N, Sawas S, Roth C, Bäumer L. Less is more: hormetic and selective antimicrobial activity of a thymoquinone-standardized black seed oil ThymoQuin in gut microbiota models. bioRxiv. May 10, 2026. doi:10.64898/2026.05.10.724082
  3. Talbott SM, Talbott JA, et al. Effect of ThymoQuin black cumin seed oil as a natural immune modulator of upper-respiratory tract complaints and psychological mood state. Food Sci Nutr Res. 2022;5(1):1-6.
  4. Talbott SM, Talbott JA. Supplementation with proprietary and patented black seed oil improves stress resilience in moderately stressed adults: an 8-week randomized, placebo-controlled study. EC Nutrition. 2026;21(3):01-09.

Related to this article

Elzaphan Hotam
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Elzaphan Hotam, director at TriNutra, about new clinical and preprint data on ThymoQuin.